Clinical Reasoning Case

Acute Decompensated Heart Failure with Preserved EF | Diagnostic Reasoning

Your Name:

How this works: This case reveals itself one stage at a time, exactly as a clinical encounter unfolds in real time. Write your response at each stage before clicking to see what comes next — your answers lock when you advance. In Stage 4A you will write your complete order set before seeing any results. Your work auto-saves to your browser. When finished, click Compile My Clinical Reasoning Report and print to PDF for submission.

Stage 1 The Admission

Patient: Dorothy Vance, 68-year-old female

Setting: Academic medical center emergency department; you are the ACNP assuming care for admission

Time: 14:30

Reason for presentation: Shortness of breath and ankle swelling, 5-day history, worsening over the past 48 hours

Referring clinician's note (ED attending, written before your evaluation): "68F with known hypertension, presenting with classic volume overload. Echo 3 years ago showed preserved EF — not a HFrEF patient. Started on furosemide 40mg IV push. Will need diuresis and discharge in 1–2 days. Likely dietary indiscretion over the holidays."

Nursing triage note: Patient accompanied by her husband. States she has been "good about her diet." Has had to sleep sitting upright in recliner for the past 4 nights because lying flat causes severe shortness of breath. Reports weight gain of 8 lbs in 5 days. Ankles "so swollen she can't get shoes on."

Stage 1: Before you enter the room

You have the triage note and the ED attending's framing. That is all you know.

List your initial differential — minimum 6 diagnoses, ranked most to least likely. For each: one sentence explaining why it belongs on this list given what you know right now. Flag any that are immediately life-threatening if missed.

Then: name the single cognitive shortcut in the ED attending's note that concerns you most — what label is being used as a diagnosis rather than a symptom?

Your Initial Differential + Anchor Trap Identification:

▶ What Would Change Your Mind

Before you click to reveal the history, commit to two answers:

What single piece of history, if present, would make you treat this as an emergent cardiology case rather than a routine diuresis admission?
The attending's note says "not a HFrEF patient" based on a 3-year-old echo. Name the specific clinical scenario where that prior echo is meaningless for today's management.

⚠️ Common Error Pathway — What Happens When Clinicians Accept the Attending's Framing

Before you read the history — these are the trajectories in structurally similar cases when "dietary indiscretion" was accepted as the working diagnosis and the prior echo was not questioned.

Error: Accepting "not a HFrEF patient" based on a 3-year-old echocardiogram

In cases where a prior normal or preserved-EF echo was used to exclude HFrEF without repeating imaging: newly developed systolic dysfunction was missed on average for 14–21 days. EF can decline acutely in the setting of hypertensive crisis, new atrial fibrillation, viral myocarditis, or ischemia — none of which can be excluded by a prior study. In published heart failure registries, approximately 30% of HFpEF patients subsequently develop HFrEF (Solomon et al., NEJM 2022). A single data point three years old is not a current EF.

In these trajectories: aggressive IV diuresis was initiated without knowing current filling pressures or EF. Patients with newly reduced EF who received rapid aggressive diuresis developed acute kidney injury (creatinine rise >0.5mg/dL in 48 hours) at a rate 2.4 times higher than those managed with repeat echo-guided therapy. Three of five patients in one case series required temporary renal replacement therapy.

Outcome: AKI from uninformed aggressive diuresis, missed new systolic dysfunction

Error: Attributing volume overload to "dietary indiscretion" and stopping the precipitant search

"Dietary indiscretion" is not a precipitant — it is a label that functions as a cognitive endpoint. In decompensated heart failure, the most common identifiable precipitants are medication non-adherence, new arrhythmia, uncontrolled hypertension, ischemia, infection, and medication additions (NSAIDs, calcium channel blockers, steroids). When "dietary indiscretion" was documented as the working etiology without a systematic precipitant search, the true trigger was found on later workup in 68% of admitted patients (Opasich et al., Eur J Heart Fail 2001). In those cases, the actual precipitant went untreated, and 30-day readmission rates were 2.1 times higher.

Outcome: Untreated precipitant, 30-day readmission rate doubled

Stage 2 History of Present Illness

Patient: Dorothy Vance, 68F

HPI — Timeline: Mrs. Vance reports 5 days of progressive shortness of breath and bilateral ankle swelling. She noticed her shoes felt tight 6 days ago. Over the past 5 days she has developed dyspnea on exertion (cannot walk to the kitchen without stopping), then dyspnea at rest, and now 4-pillow orthopnea requiring sleeping upright in her recliner. She reports waking at night with shortness of breath that is relieved when she sits up (paroxysmal nocturnal dyspnea). She weighed herself this morning: 8 lbs heavier than one week ago. She denies chest pain, palpitations, syncope, or fever.

Precipitant history — specifically queried:

Medication change 3 weeks ago: Her rheumatologist added naproxen 500mg twice daily for a flare of osteoarthritis. She has been taking it every day since. No one told her it could affect her heart.
Adherence to prior medications: Takes all her prescribed medications daily. Denies missed doses. Has her husband confirm — he verifies she takes her medications each morning.
Salt intake: "I eat what I always eat. I don't add salt." Husband corroborates. No holiday gatherings, no known high-sodium meals.
New symptoms preceding decompensation: No recent upper respiratory illness. No fever. No dysuria. No chest pain. Reports she "felt fine" until 6 days ago.

Past Medical History:

Heart failure with preserved ejection fraction (HFpEF) — diagnosed 3 years ago after presenting with similar dyspnea; echocardiogram at that time showed EF 60%, grade I diastolic dysfunction, LVH
Hypertension — longstanding, on three agents at home
Obesity — BMI 33
Type 2 diabetes mellitus — on metformin; last HbA1c 7.4%
Chronic kidney disease stage 3a — baseline creatinine 1.2 mg/dL (per records from 6 months ago)
Osteoarthritis, bilateral knees — newly started on naproxen 3 weeks ago
No prior myocardial infarction. No prior atrial fibrillation. No known coronary artery disease.

Home Medications (pharmacy reconciliation, confirmed with husband):

Lisinopril 10mg daily
Amlodipine 5mg daily
Hydrochlorothiazide 25mg daily
Metformin 1000mg twice daily
Aspirin 81mg daily
Naproxen 500mg twice daily — added 3 weeks ago by rheumatologist
No loop diuretic at home. No beta-blocker. No SGLT2 inhibitor.

Allergies: Penicillin — hives. No other known drug allergies.

Social History: Married, lives with husband. Retired teacher. Non-smoker. No alcohol. No illicit substance use.

Family History: Mother with hypertension and heart failure, died age 78. Father with type 2 diabetes.

Review of Systems: Positive: dyspnea, orthopnea, PND, leg edema, weight gain, fatigue. Negative: chest pain, palpitations, syncope, fever, cough, hemoptysis, leg pain, recent illness.

Stage 2: What the history tells you

You have the full history. Three specific tasks — not a re-ranking of your full differential:

1. Precipitant search: List every decompensation precipitant you can identify from the history alone. For each, write one sentence on the specific mechanism by which it caused or worsened volume overload in this patient.

2. Revised differential: For your top 3 diagnoses, cite one real landmark study, ACC/AHA guideline, or validated tool directly relevant to this patient (author, year, journal, specific finding that applies here).

3. The HFpEF problem: The prior echo showed preserved EF. Explain in 2–3 sentences why preserved EF does not mean normal cardiac function, and what specific pathophysiology drives volume overload in HFpEF.

Precipitant Search + Revised Differential with Evidence + HFpEF Pathophysiology:

▶ What Would Change Your Mind

Before advancing to the physical exam, commit to two answers:

What vital sign abnormality, if present on exam, would immediately change this from a routine diuresis admission to an acute hemodynamic emergency requiring ICU-level care?
The naproxen was started 3 weeks ago. Explain the specific pharmacologic mechanism by which an NSAID causes acute decompensation in a patient with pre-existing HFpEF.

⚠️ Common Error Pathway — What Happens When the Precipitant Search Is Incomplete

The history contains the most modifiable precipitant in this case. Missing it leads to a predictable outcome trajectory.

Error: Naproxen not identified as the primary precipitant — continued through hospitalization

NSAIDs inhibit renal prostaglandin synthesis, reducing GFR and impairing free water excretion. They also blunt natriuretic peptide responsiveness, increase systemic vascular resistance, and directly antagonize the mechanism of action of loop diuretics. In patients with pre-existing CKD and HFpEF, the combination of hydrochlorothiazide and naproxen creates competing fluid-retention and diuresis signals that can produce net positive balance even in the presence of diuretic therapy. This effect is dose-dependent and persists as long as the NSAID is administered.

In cases where naproxen was continued: IV furosemide produced an adequate first-dose diuresis (1.2L UOP in 6 hours) but patients re-accumulated fluid overnight. The hospitalist attributed the re-accumulation to "inadequate diuresis" and doubled the furosemide dose. Creatinine rose from 1.2 to 2.1 mg/dL by HD2 — a cardiorenal syndrome type 1 pattern driven entirely by excessive diuresis in the presence of a drug blocking the underlying mechanism. The naproxen was not discontinued until a pharmacist flag on HD3. By then, renal function required nephrology consultation and diuresis was suspended.

Outcome: Cardiorenal syndrome, creatinine 2.1, nephrology consult, extended LOS

Error: Metformin continued despite acute volume overload and CKD

Metformin is contraindicated when eGFR falls below 30 mL/min/1.73m² and should be held when acute volume depletion, contrast administration, or acute hemodynamic instability is anticipated. In a patient with baseline CKD stage 3a (eGFR estimated ~45–55) presenting with acute decompensation and now receiving IV diuretics, eGFR may transiently fall below the safety threshold. Lactic acidosis from metformin accumulation is rare but is associated with mortality rates of 30–50% when it occurs. The correct action is to hold metformin on admission in any acute illness with volume flux — this is a zero-cost intervention.

Outcome: Lactic acidosis risk, required urgent endocrinology guidance HD2

Stage 3 Vital Signs, Physical Examination & Bedside Assessment

Vital Signs (on arrival to medicine floor, 15:15)

Blood Pressure: 188/110 mmHg (ED triage: 194/112)
Heart Rate: 94 bpm, regular
Respiratory Rate: 24 breaths/min
SpO₂: 91% on room air, improves to 95% on 2L NC
Temperature: 37.1°C
Weight: 84.2 kg (her reported dry weight 3 months ago: 75.4 kg — net gain of 8.8 kg / ~19 lbs)

Physical Examination

General: Obese female, seated upright, mildly distressed, speaking in short phrases due to dyspnea. Alert and oriented x4. Anxious but cooperative.

HEENT: No JVD in sitting position. Jugular veins assessed supine — estimated JVP 12 cm H₂O at 45 degrees (elevated). Moist oral mucosa. No scleral icterus.

Cardiovascular: Regular rate and rhythm. S1/S2 present. S4 gallop clearly audible at apex. No murmur, no rub. Radial pulses 2+ bilaterally. No pulsus paradoxus. Capillary refill 2.5 seconds bilaterally.

Pulmonary: Bilateral crackles to mid-lung fields, left greater than right. No wheeze. No dullness to percussion. Respiratory rate 24, with accessory muscle use on deep inspiration.

Abdomen: Obese, soft. Hepatomegaly palpated 3 cm below right costal margin, mildly tender. No splenomegaly. No ascites by percussion. Bowel sounds present.

Extremities: 3+ pitting edema bilateral lower extremities to the knees. Skin intact. No erythema. No calf tenderness bilaterally. Bilateral posterior tibial pulses 2+ and dorsalis pedis pulses 1+.

Skin: No rash. No petechiae. Mild skin tightness over bilateral shins from edema. No skin breakdown.

Neurological: Alert and oriented x4. Cranial nerves II–XII grossly intact. No focal deficits. No dysarthria.

Bedside Hemodynamic Classification — Nohria-Stevenson Framework

Parameter	Assessment	Finding
Congestion ("wet vs. dry") JVP, crackles, edema, orthopnea, PND	JVP 12 cm, bilateral crackles to mid-lung, 3+ bilateral edema, 4-pillow orthopnea, PND	WET ✓
Perfusion ("warm vs. cold") MAP, extremity temperature, CRT, pulse pressure	BP 188/110, pulse pressure 78 (adequate), CRT 2.5 sec (borderline), extremities warm, no mottling	WARM ✓
Profile	Wet + Warm	Profile B — Congested, Adequate Perfusion

Clinical implication: Profile B (Wet-Warm) is the most common acute decompensated heart failure presentation. Diuresis is the primary intervention. Vasodilators are appropriate adjuncts given elevated BP. Inotropes are NOT indicated — perfusion is preserved. The key risk is aggressive diuresis outpacing renal tolerance, particularly given underlying CKD and NSAID use.

Stage 3: Exam findings — three questions only

1. The Nohria-Stevenson Profile is B (Wet-Warm). What does this confirm — and critically, what does it not tell you? What must you still investigate before prescribing a diuresis strategy?

2. The blood pressure is 188/110. Name your three most urgent clinical actions right now, before any lab results return. For each, state the specific clinical reason in the context of this patient.

3. What is your "must not miss" diagnosis that the current presentation does not rule out? Name the one exam finding, if different, that would require immediate cardiology at the bedside rather than a routine page.

Hemodynamic Profile Interpretation + Three Urgent Actions + Must-Not-Miss:

Clinical note: BP 188/110 + SpO₂ 91% + bilateral crackles + S4 gallop + 8.8 kg weight gain = acute decompensated HFpEF with hypertensive trigger. The blood pressure is both a finding and a cause — uncontrolled hypertension increases left ventricular afterload, impairs diastolic relaxation, and directly worsens pulmonary congestion. Treating the blood pressure is treating the heart failure.

▶ What Would Change Your Mind

Before writing orders:

What specific lab result would change this from oral diuretic management to urgent nephrology consultation?
What metabolic abnormality is most likely given this patient's medication list, and which single lab confirms or excludes it?
Should imaging come before or after metabolic labs — and in what clinical scenario would you reverse that sequence?

⚠️ Common Error Pathway — What Happens When the Exam Findings Drive the Wrong First Response

The physical exam provided three urgent findings that each demand specific action before any pharmacologic escalation. Missing any one produces a distinct consequence.

Error: Aggressive IV furosemide without knowing current renal function or electrolytes

Furosemide 80mg IV ordered on arrival without waiting for a basic metabolic panel in a patient with known CKD stage 3a and 3 weeks of NSAID use. By the time the BMP resulted (K 3.1, Cr 1.8), the patient had already received the first dose. The loop diuretic induced kaliuresis on top of a borderline-low potassium, producing K 2.8 by evening labs. At K <3.0 in a patient with significant hypertension and presumed LVH, the risk of ventricular arrhythmia — specifically torsades de pointes — is clinically significant. The attending was called urgently at 20:00 for a new run of ventricular bigeminy on the telemetry monitor.

Outcome: Hypokalemia-induced ventricular bigeminy, emergent potassium repletion, cardiac monitoring escalation

Error: Chest X-ray ordered before BMP and BNP — imaging used as the primary diagnostic tool

When chest X-ray was ordered first and returned showing "bilateral interstitial infiltrates consistent with pulmonary edema," this was used to confirm the HF diagnosis and close the workup. The BNP was ordered 4 hours later as an afterthought and returned at 2,840 pg/mL — but no one rechecked whether hypokalemia, AKI, or a new arrythmia had developed in the interim, because the imaging had provided the desired confirmation. Imaging should follow metabolic labs, not precede them — the BMP answers questions about safety of diuresis that no imaging study can answer.

Outcome: AKI from diuresis without metabolic baseline, 4-hour delay to electrolyte correction

Error: Blood pressure left unaddressed pending "response to diuresis"

BP 188/110 was documented but no antihypertensive intervention was ordered, with the rationale that "diuresis will bring the blood pressure down." In a patient with HFpEF, hypertension is both a precipitant and a maintenance mechanism of decompensation — elevated afterload impairs diastolic relaxation and sustains elevated LV filling pressures regardless of volume status. Diuresis alone reduces preload but does not reduce afterload. In patients where BP remained >160 systolic after 6 hours of diuresis, clinical trials show diuretic response is significantly impaired compared to patients whose BP was controlled concurrently (Inampudi et al., Circ Heart Fail 2018). The most immediately reversible, zero-cost first step: optimize the blood pressure now.

Outcome: Impaired diuretic response, prolonged LOS, ongoing diastolic dysfunction maintenance

Stage 4A Diagnostic & Immediate Management Orders

Clinical context: It is 15:30. Mrs. Vance is on telemetry. She has not yet received any medications from you — the ED furosemide 40mg IV was given at 14:00 (90 minutes ago; she reports urinating once since arrival, ~300mL). Peripheral IV is in place. You are the ACNP of record. All diagnostic tests and treatment orders require your explicit order with documented rationale. No laboratory results are available to you at this moment.

⚑ Sequencing Flag — Faculty Note

The most common sequencing error in acute decompensated HFpEF: administering aggressive IV loop diuresis before obtaining a basic metabolic panel in a patient with known CKD and NSAID use. The metabolic panel determines starting potassium (critical for safe diuresis), baseline creatinine trajectory, and initial eGFR. Ordering diuretics first and labs second inverts this sequence and introduces preventable harm. A close second: ordering CT chest or repeat chest X-ray before BNP, BMP, and urinalysis — imaging answers the wrong question first.

Write Your Complete Order Set — Before Seeing Any Results

Based on the history, physical exam, Nohria-Stevenson profile, and your current differential: write your complete diagnostic workup and immediate management orders. For each diagnostic test, state the specific clinical question it answers. For each intervention, state the goal.

Consider: What must you know before escalating diuresis? Which medication from the home list requires a STOP order now? Is a repeat echocardiogram indicated, and if so, what specific information do you need from it?

Stage 4B Laboratory & Imaging Results

Laboratory Results (16:15 — approximately 45 minutes after admission orders)

Basic Metabolic Panel:
Na 139 | K 3.3 (low-normal — caution before loop diuresis) | Cl 99 | CO₂ 26 | BUN 32 | Creatinine 1.8 (baseline 1.2 — KDIGO Stage 1 AKI: 1.5× baseline, consistent with NSAID-induced renal vasoconstriction) | Glucose 168

CBC:
WBC 9.2 | Hgb 12.8 | Hct 38.3 | Plt 242

Cardiac Biomarkers:
BNP 2,840 pg/mL (strongly elevated; normal <100 pg/mL; values >400 pg/mL in the setting of acute dyspnea are >95% specific for heart failure as the etiology) | Troponin I 0.04 ng/mL (upper limit of normal 0.04 — borderline, requires repeat in 3 hours to exclude NSTEMI)

Lipid Panel:
LDL 118 mg/dL | HDL 44 | Triglycerides 188 | Total cholesterol 201

Thyroid Function:
TSH 2.4 mIU/L (normal) — hypothyroidism excluded as precipitant

HbA1c: 7.8% (slight increase from 7.4% three months ago)

Urinalysis:

Color: Yellow, clear | Specific gravity: 1.024 | pH: 5.5 Leukocyte esterase: Negative | Nitrite: Negative Protein: 2+ | Blood: Negative | Glucose: 2+ ──────────────────────────────────────────────── Microscopy: 2-4 RBC/hpf | 0-2 WBC/hpf | No casts | No bacteria Interpretation: Proteinuria consistent with CKD and/or acute hypertensive nephropathy. No evidence of UTI. No red cell casts (excludes active glomerulonephritis).

12-Lead ECG (16:00):
Normal sinus rhythm, rate 92. LVH by voltage criteria (Sokolow-Lyon criteria met: SV1 + RV5 = 38mm). No ST-segment changes. No Q waves. QTc 448ms. No acute ischemic changes.

Chest X-Ray (16:30)

Report: Cardiomegaly (cardiothoracic ratio 0.58). Bilateral interstitial and alveolar infiltrates, left greater than right, consistent with pulmonary edema. Bilateral pleural effusions, small-moderate. Vascular redistribution to upper lobes. No pneumothorax. No consolidation to suggest pneumonia. Mediastinum normal. Aortic knob prominent — consistent with longstanding hypertension.

Paradox requiring interpretation: Creatinine is 1.8 — 50% above baseline — at the time of admission, before you have given any additional diuresis. The ED furosemide (given 90 minutes ago) has produced approximately 300mL UOP. However, the AKI preceded your diuresis. This AKI is pre-renal from NSAID-mediated renal vasoconstriction — not from diuretic over-treatment. Understanding this distinction is essential: the reflex response to rising creatinine is to hold diuretics, but in this case, stopping diuresis without stopping the NSAID leaves the primary mechanism intact and the patient continues to accumulate volume. The NSAID must stop first. Diuresis, titrated carefully with electrolyte monitoring, should continue.

Stage 4B: The comprehensive synthesis — this is the clinical reasoning core of the case

Four required elements:

1. Bayesian update: For each major result — BNP 2,840, Creatinine 1.8, Troponin borderline, K 3.3, LVH on ECG — state what it does to the probability of each diagnosis on your current differential.

2. Complete precipitant and contributor inventory: List ALL identifiable precipitants and contributing factors. For each: classify by type (pharmacologic / hemodynamic / metabolic / behavioral), and rank by (a) immediacy of harm and (b) reversibility.

3. Final diagnosis with subtype: State your final diagnosis precisely — include HF subtype, hemodynamic profile, KDIGO AKI stage, and all contributing etiologies.

4. Treatment plan: Nonpharmacologic interventions first (with evidence). Then pharmacologic — for each drug class, state when indicated, when contraindicated, and what to avoid in this specific patient and why.

Bayesian Update + Precipitant Inventory + Final Diagnosis + Treatment Plan:

⚠️ Common Error Pathway — What Happens When Labs Drive the Wrong Conclusions

Three distinct errors in interpreting these specific results — each leading to a measurably different trajectory.

Error: Treating the creatinine rise by holding diuretics without stopping the NSAID

When creatinine 1.8 triggered a hold on IV furosemide without a concurrent stop order for naproxen, the patient's volume overload continued to worsen overnight. By morning: weight up an additional 1.6 kg, SpO₂ 88% on 2L NC, respiratory rate 28. Creatinine on morning labs: 2.1 mg/dL. The hospitalist reasoning was: "creatinine rising, likely diuretic-induced AKI, hold diuretics." This reasoning is correct for diuretic-induced AKI but incorrect here — the AKI was NSAID-mediated renal vasoconstriction. Stopping diuretics without stopping the causative NSAID left the primary mechanism untreated and worsened pulmonary edema to the point requiring non-invasive ventilation at 06:00 on HD2.

Outcome: BiPAP for pulmonary edema, MICU transfer, 9-day LOS

Error: Treating K 3.3 with aggressive IV potassium before establishing diuresis plan

Potassium 3.3 is low-normal and requires monitoring and oral supplementation — not emergent IV repletion before diuresis. When IV KCl 40mEq was administered in 250mL NS over 4 hours as the first intervention (before diuresis was established), this delayed the start of loop diuresis by 4 hours and introduced 250mL additional volume. The patient's respiratory status worsened slightly during repletion. The standard approach: oral potassium supplementation (40mEq KCl orally), add potassium monitoring to diuresis orders, and adjust diuresis dose based on the metabolic trajectory. IV repletion is for K <3.0 or symptomatic hypokalemia — not K 3.3.

Outcome: 4-hour delay to diuresis, 250mL additional volume load, worsening dyspnea during repletion

Error: The most immediately reversible, zero-cost intervention omitted — naproxen not stopped

In published acute heart failure case series, medication-induced decompensation accounts for 20–30% of all admissions. In those cases where the offending agent was stopped within the first 6 hours of admission, hospital length of stay averaged 3.4 days shorter than cases where the agent was continued or identified after HD1. The NSAID was ordered by a specialist who did not know the patient's cardiovascular history. The primary team had the complete medication list. The stop order cost nothing, required no lab result, no imaging, and no consultation — and it was the single most important management action in this case.

Outcome: The absence of a STOP order for naproxen is the most preventable error in this case — zero cost, maximum impact, missed on first encounter in 40% of similar cases

Stage 5 Clinical Evolution — Hospital Days 1 through 3

Hospital Course (when correct interventions were applied)

HD1 — 17:00 (2.5 hours after admission):

Naproxen stopped immediately on admission. No analgesic substituted at this time — pain is not acute. Husband educated about why the NSAID caused this hospitalization.
Metformin held given AKI and volume flux. Endocrinology aware.
Blood pressure management initiated: Home amlodipine continued. IV nicardipine drip started for BP >180 systolic, targeting 140–150 systolic — adequate acute reduction without precipitous drop in a patient with LVH-associated impaired diastolic filling.
Diuresis strategy: After BMP resulted, K 3.3 addressed with oral KCl 40mEq. IV furosemide 80mg (twice the home-equivalent dose) started after electrolytes confirmed. Goal: 1–1.5L negative daily balance, reassess daily with weight and creatinine trend.
Oxygen: 2L NC continued, titrated to SpO₂ ≥95%.
Nonpharmacologic: Head of bed elevated 30–45 degrees. Leg elevation with bed-end tilt. Sodium restriction 2g/day initiated. Daily weights ordered. Strict I&Os.
Troponin serial monitoring: 3-hour repeat troponin 0.03 ng/mL (decreased — NSTEMI excluded, troponin elevation attributed to myocardial wall stress from volume overload and hypertension).

HD1 — Evening assessment: Urine output 1,800mL in 8 hours. Weight down 1.4 kg from peak. BP 152/94. SpO₂ 95% on 2L. Patient reports "breathing is easier — I can talk in full sentences." Creatinine repeat: 1.6 mg/dL (trending down as NSAID effect clears).

HD2 — Morning:

Weight: 80.8 kg (-3.4 kg from admission). Net UOP overnight: 1.6L negative.
BP: 144/88 on nicardipine drip plus home amlodipine.
SpO₂: 96% on room air — oxygen weaned.
Creatinine: 1.4 mg/dL (trending toward baseline).
K: 3.6 (oral potassium supplementation effective).
Patient ambulating to bathroom without dyspnea. Sleeping flat with 2 pillows.
Echocardiogram ordered: EF 55%, unchanged from 3 years ago — no new systolic dysfunction. Grade II diastolic dysfunction. Moderate LVH. Elevated E/e' ratio (14) confirming elevated LV filling pressures. No effusion. No structural lesion.

HD2 — Afternoon:

Nicardipine drip weaned as oral BP medications adjusted: lisinopril increased from 10mg to 20mg daily (ACE inhibitor remains foundational in HFpEF with hypertension and CKD). Amlodipine continued at 5mg. HCTZ held (redundant with loop diuretic during active diuresis; will reassess at discharge).
SGLT2 inhibitor initiated: Empagliflozin 10mg daily — evidence-based per EMPEROR-Preserved trial (Anker et al., NEJM 2021); reduces HF hospitalization in HFpEF, has modest diuretic effect, and is renoprotective once creatinine stabilizes.
Cardiology consult completed: confirmed HFpEF diagnosis, agreed with management plan, recommended outpatient cardiac rehabilitation referral and repeat echo in 3 months.
Pain management discussed: naproxen and all NSAIDs permanently contraindicated. Safe alternatives for osteoarthritis: acetaminophen 500mg TID (scheduled, not PRN), topical diclofenac for local joint application (minimal systemic absorption), referral to physical therapy. Rheumatology notified in writing.

HD3 — Discharge assessment:

Weight: 77.2 kg (-7.0 kg from admission, -2.2 kg from her reported dry weight 3 months ago — consistent with some pre-hospital chronic volume accumulation from NSAID use).
BP: 138/86. SpO₂: 97% room air. HR 78, regular.
Creatinine: 1.3 mg/dL (approaching baseline 1.2).
BNP on discharge: 890 pg/mL (down from 2,840 — still elevated above normal, reflecting residual diastolic dysfunction, but 68% reduction from admission).
Ambulating full flight of stairs without dyspnea. Sleeping flat with 1 pillow.

Discharge medications: Lisinopril 20mg daily — Amlodipine 5mg daily — Furosemide 20mg daily (new, oral) — Empagliflozin 10mg daily (new) — Aspirin 81mg daily — Metformin resumed at discharge with CKD precautions documented — KCl 20mEq daily (for 2 weeks, then reassess) — HCTZ discontinued (redundant with furosemide). NSAID class permanently contraindicated — documented in allergy/intolerance section.

Discharge disposition: Home with husband. Close outpatient follow-up in 1 week with primary care and cardiology. Cardiac rehabilitation referral. Heart failure nurse navigator enrolled. Scale at home — daily weights. Return to ED for weight gain >3 lbs in 2 days or worsening dyspnea.

Stage 5: Final synthesis — three required elements

1. Reasoning chain: Trace your complete clinical reasoning from Stage 1 through Stage 5 — what data at each stage moved you toward or away from each diagnosis.

2. Cognitive bias identification: Name the specific cognitive bias engineered into this case at Stage 1. Explain the precise mechanism by which it was designed to mislead. Describe what you would need to consciously do differently the next time you receive a handoff with a pre-existing label.

3. Clinical lesson generalization: Complete this sentence — and make it specific, not generic: "The next time I see a patient admitted with acute decompensated heart failure and a prior preserved-EF echo, I will specifically..."

Reasoning Chain + Cognitive Bias + Clinical Lesson:

⚠️ The Wrong Path — Complete Composite Trajectory

What the entire 5-day course looks like when every stage goes wrong. Dorothy's baseline: independent, living with her husband, volunteers at her church's literacy program three mornings a week. Retired teacher. Still drives. This is the contrast point.

The 9-day course when the anchor held and the NSAID stayed

HD1: "Dietary indiscretion" accepted. Naproxen continued. Furosemide 80mg IV given without BMP — K 3.1 found 4 hours later; 40mEq IV repletion delayed diuresis by 3 hours. No BP management — "will respond to diuresis." UOP: 1.1L. Weight unchanged.

HD2: Creatinine 2.1 (rising despite modest diuresis — NSAID effect unchecked). "Cardiorenal syndrome" documented. Furosemide held. Volume status worsening. SpO² 88% on 2L overnight — BiPAP initiated at 0500. Patient transferred to MICU. Agitated and frightened. Husband not permitted at bedside overnight per unit policy.

MICU HD3–HD5: Nephrology consulted. Creatinine peaked at 2.6. NSAID finally identified by pharmacist on HD4 and discontinued. IV diuresis restarted cautiously. BNP 3,100. Echo ordered — EF 54%, consistent with HFpEF, diastolic dysfunction Grade II. BiPAP weaned HD5. Creatinine trending down. Patient exhausted, deconditioned from 3 days bedrest in MICU.

HD6–HD9 (medical floor after MICU step-down): Continued diuresis. Physical therapy consulted for deconditioning — patient requires assist of one for ambulation (was fully independent). Weight goal not achieved until HD8. Discharge delayed by functional decline and inability to ambulate independently to bathroom. Occupational therapy recommends home PT and possible short-term rehab evaluation.

Discharge (HD9): To short-term rehabilitation facility — not home. Dorothy cannot safely navigate stairs to her bedroom. She will not be driving. Her literacy program mornings on hold. Her husband, 72, now needs to arrange his own care while she is in the facility. The 9-day course, the MICU stay, the short-term rehab placement — all of it traces back to a stop order that was never written on HD1.

Outcome: 9-day LOS, MICU transfer, short-term rehab, functional decline, driving suspended — driven by a single missed STOP order

Stage 6 Expert Debrief — Faculty Synthesis

No student task in this stage. This is the faculty synthesis. Read it after completing your reasoning report above.

1. What This Case Was Testing — The Cognitive Bias Engineered In

This case was engineered around framing bias (also called framing effect or anchoring to a frame), a specific subtype of anchoring bias. The ED attending's note did two things simultaneously: it provided a diagnostic conclusion ("volume overload, likely dietary indiscretion") and it preemptively closed a diagnostic pathway ("not a HFrEF patient"). Both statements were presented as established facts — neither required documentation or justification in the note. When a consulting clinician receives a handoff that frames the problem as solved, the natural cognitive tendency is to work within that frame rather than to reconstruct the problem from first principles.

The phrase "dietary indiscretion" is the anchor. It is presented as if it is a diagnosis. It is not. "Dietary indiscretion" is a social attribution that assigns causation to the patient's behavior without a systematic precipitant search. In published literature, when this phrase appears in admission notes, a pharmacologic precipitant search was documented in fewer than 20% of cases (Opasich et al., 2001). The patient was a retired teacher who told you explicitly that her diet had not changed. Her husband confirmed this. The clinician who accepted "dietary indiscretion" ignored the patient's own testimony in favor of the attending's framing.

The countermeasure: when receiving any handoff with a pre-existing label, the correct practice is to explicitly reconstruct the differential from the raw data before accepting the framing — even when the framing seems plausible, even when the clinician is senior to you.

2. Why "HFpEF" Is a Description, Not a Diagnosis — and Why the Prior Echo Matters Less Than You Think

Heart failure with preserved ejection fraction (HFpEF) describes the finding that the left ventricle ejects a normal or near-normal fraction of its end-diastolic volume. It says nothing about: (1) whether the LV can fill normally under stress, (2) whether filling pressures are elevated, (3) whether the EF has changed since the last study, or (4) what is causing the current episode of decompensation.

In HFpEF, the fundamental pathophysiology is impaired diastolic relaxation — the LV becomes stiff (from hypertrophy, fibrosis, or both) and cannot relax quickly enough during diastole to accommodate venous return at normal filling pressures. The EF is preserved because systolic contraction is intact — but filling pressures rise, pulmonary venous congestion develops, and the clinical picture of heart failure follows. This is why antihypertensive therapy (reducing afterload, allowing LV remodeling) is foundational — the disease is driven by pressure overload, not by systolic dysfunction.

The prior echo in this case was 3 years old. New systolic dysfunction can develop acutely from ischemia, myocarditis, or tachycardia-induced cardiomyopathy — none of which would be visible on an old study. A repeat echocardiogram is warranted in any ADHF presentation where EF status may have changed or where therapeutic decisions depend on knowing current filling pressures and structural findings.

3. The Nohria-Stevenson Framework — Evidence, Interpretation, and Limitations

The Nohria-Stevenson hemodynamic classification (Nohria et al., Circulation 2003) stratifies acute heart failure patients into four profiles based on two clinical axes: congestion ("wet vs. dry") and perfusion ("warm vs. cold"). Profile B (Wet-Warm), as in this patient, identifies congestion without hypoperfusion — the most common ADHF presentation, and the one most amenable to diuresis and afterload reduction without inotropic support.

What it confirms: The hemodynamic state at the time of assessment. Profile B patients can be safely diuresed and benefit from vasodilator therapy (particularly when BP is elevated). In-hospital mortality for Profile B is lower than Profiles C and L.

What it does NOT tell you: The cause of decompensation. The safety of diuresis given renal function. The current EF. Whether an NSAID is blocking your diuretic's mechanism of action. Hemodynamic classification is a snapshot — it guides the initial treatment strategy but does not substitute for a complete precipitant evaluation.

Limitations: Bedside assessment of JVP is notoriously inaccurate — estimated 40–50% sensitivity in some studies. BNP, point-of-care echo, and lung ultrasound (comet-tail sign for pulmonary edema) improve accuracy when the clinical picture is ambiguous.

4. The NSAID-Heart Failure Interaction — Pharmacologic Mechanism

NSAIDs block cyclooxygenase enzymes (COX-1 and COX-2), reducing synthesis of prostaglandins E2 and I2 in the kidney. These prostaglandins serve as local vasodilators that maintain renal afferent arteriolar tone in states of low flow — including heart failure, where neurohumoral activation (renin-angiotensin-aldosterone system, sympathetic nervous system) is already producing renal vasoconstriction. When NSAIDs block this compensatory vasodilation, GFR falls. Sodium and water retention follow. Effective blood volume appears reduced to the kidney, triggering further RAAS activation — creating a feedback loop.

Three simultaneous mechanisms converge: (1) direct renal vasoconstriction, (2) sodium and water retention that worsens volume overload, and (3) direct antagonism of loop diuretic efficacy — furosemide and other loop diuretics depend partly on prostaglandin-mediated vasodilation in the loop of Henle; NSAIDs blunt this effect, reducing diuretic response by 30–50% in some studies. In a patient with pre-existing CKD and HFpEF, who is also on HCTZ (a thiazide), these mechanisms compound into a clinically significant reduction in net fluid excretion — explaining why an otherwise well-compensated patient decompensated within 3 weeks of starting the NSAID.

The 2022 ACC/AHA/HFSA Heart Failure Guideline assigns NSAIDs in heart failure a Class III: Harm recommendation — they are contraindicated. This applies to all NSAIDs, including topical agents used at higher doses. The rheumatologist's prescription in this case occurred without cardiovascular context — the communication failure between specialties was the system-level precipitant.

5. Evidence-Based Management of Acute Decompensated HFpEF — The Nonpharmacologic Bundle

For HFpEF, the evidence base for pharmacologic therapy is thinner than for HFrEF. The nonpharmacologic bundle remains foundational:

Sodium restriction (2g/day): Standard of care; reduces osmotic pressure driving fluid retention. Patient education essential — hidden sodium sources (canned goods, restaurant meals, processed foods) are frequent contributors to recurrence.
Daily weights: The most actionable self-monitoring tool. A 2–3 lb overnight gain in the absence of other explanation represents approximately 1 liter of retained fluid. Early detection and same-day medication adjustment (uptitration of home loop diuretic) is the primary driver of reducing 30-day readmission.
Fluid restriction: Typically 1.5–2L/day in moderate-to-severe congestion; less relevant in mild cases. Most important during active decompensation.
Leg elevation: Reduces dependent edema, improves venous return during the day without contributing to nocturnal redistribution (which is already managed with head-of-bed elevation).
Exercise and cardiac rehabilitation: HF-ACTION trial (O'Connor et al., JAMA 2009) demonstrated modest but significant improvement in exercise tolerance and quality of life. Cardiac rehab referral is an evidence-based component of discharge planning for all NYHA class II–III HF patients.
Heart failure disease management program enrollment: Systematic reviews consistently show 20–30% reduction in HF readmission when patients are enrolled in structured follow-up with nurse navigators, weight monitoring protocols, and phone-based titration authority.

6. Pharmacologic Management — What Is Indicated, What Is Contraindicated, and Why

Loop diuretics (furosemide): First-line for symptom relief in acute congestion. IV formulation in the hospital for reliable bioavailability. DOSE trial (Felker et al., NEJM 2011): high-dose strategy (2.5× home dose) produces greater symptom relief without significantly worse renal outcomes in most patients. Electrolyte monitoring is mandatory.

RAAS inhibition (ACE inhibitor — lisinopril): Indicated in HFpEF with hypertension and CKD. Reduces both afterload and natriuretic peptide levels. Dose uptitration at discharge supported by evidence. Continue unless creatinine exceeds 30% rise from baseline or K >5.5.

SGLT2 inhibitors (empagliflozin, dapagliflozin): EMPEROR-Preserved (Anker et al., NEJM 2021) and DELIVER (Solomon et al., NEJM 2022) both demonstrated significant reduction in composite outcome of HF hospitalization or cardiovascular death in HFpEF — the first drug class to do so. Mechanism includes glucosuria-driven osmotic diuresis, reduced RAAS activation, direct cardiac metabolic effects, and renoprotection. Hold if eGFR <20. Safe to initiate once acute AKI is resolving.

NSAIDs (naproxen, ibuprofen, celecoxib, all others): Class III: Harm in heart failure. Mechanism reviewed above. Permanently contraindicated. Must be documented in the allergy/intolerance section of the medical record — not merely mentioned in the discharge note — so that future prescribers encounter the warning at the point of prescribing.

Calcium channel blockers (non-dihydropyridine: diltiazem, verapamil): Contraindicated in heart failure with reduced EF. In HFpEF, they are not beneficial and can worsen heart rate response. Amlodipine (dihydropyridine) is safe in HFpEF and appropriate for BP management.

Digoxin: No benefit in HFpEF. Associated with harm in women specifically (Rathore et al., NEJM 2002). Do not initiate.

Nitrates: Appropriate adjunct for hypertensive ADHF when BP >180 and rapid BP reduction is needed (sublingual nitroglycerin, IV nitroglycerin, or IV nicardipine). Avoid in right heart failure, hemodynamically significant aortic stenosis, or if patient has taken a PDE5 inhibitor within 24–48 hours.

7. Landmark Evidence — Key Trials and Guidelines in HFpEF

Reference	Key Finding Relevant to This Case
Anker et al., NEJM 2021 EMPEROR-Preserved	Empagliflozin 10mg reduced composite of CV death or HF hospitalization by 21% in HFpEF (EF >40%). First Class I recommendation for a drug specifically in HFpEF.
Solomon et al., NEJM 2022 DELIVER Trial	Dapagliflozin 10mg reduced HF hospitalization by 23% in HFpEF — confirmed SGLT2i benefit across the EF spectrum. Also showed that approximately 30% of HFpEF patients had subsequent EF decline to <40% on follow-up.
Felker et al., NEJM 2011 DOSE Trial	High-dose IV furosemide strategy (2.5× home dose) vs. low-dose produced greater symptom relief and dyspnea improvement at 72 hours without significantly worse renal outcomes. Informs initial diuresis dosing in ADHF.
Nohria et al., Circulation 2003 Hemodynamic Classification	Developed the 4-profile Wet/Dry Warm/Cold framework. Profile B (Wet-Warm) associated with intermediate prognosis; Profile C (Wet-Cold) highest in-hospital mortality. Clinical classification at bedside guides initial therapy without invasive monitoring.
Opasich et al., Eur J Heart Fail 2001	In 1,317 ADHF admissions, identifiable non-dietary precipitants (arrhythmia, medication non-adherence, infection, iatrogenic factors) were found in 68% of patients initially attributed to "dietary indiscretion." Systematic precipitant search reduces 30-day readmission.
2022 ACC/AHA/HFSA Heart Failure Guideline Heidenreich et al., Circulation 2022	NSAIDs: Class III Harm recommendation in all heart failure subtypes. SGLT2 inhibitors: Class IIa for HFpEF (EF ≥50%). Loop diuretics for volume overload: Class I. RAAS inhibition for comorbid hypertension in HFpEF: Class I.
Inampudi et al., Circ Heart Fail 2018	Uncontrolled hypertension on admission (SBP >160) was independently associated with significantly impaired diuretic response in ADHF, even after adjustment for congestion severity. Concurrent BP management improved diuretic efficacy in hypertensive ADHF.
O'Connor et al., JAMA 2009 HF-ACTION Trial	Exercise training in stable HF patients reduced all-cause mortality and hospitalization by 11% at 2.5-year follow-up. Cardiac rehabilitation referral is a guideline-supported component of discharge planning.

Clinical Reasoning Case

Patient: Dorothy Vance, 68F

Vital Signs (on arrival to medicine floor, 15:15)

Physical Examination

Bedside Hemodynamic Classification — Nohria-Stevenson Framework

Laboratory Results (16:15 — approximately 45 minutes after admission orders)

Chest X-Ray (16:30)

Hospital Course (when correct interventions were applied)

1. What This Case Was Testing — The Cognitive Bias Engineered In

2. Why "HFpEF" Is a Description, Not a Diagnosis — and Why the Prior Echo Matters Less Than You Think

3. The Nohria-Stevenson Framework — Evidence, Interpretation, and Limitations

4. The NSAID-Heart Failure Interaction — Pharmacologic Mechanism

5. Evidence-Based Management of Acute Decompensated HFpEF — The Nonpharmacologic Bundle

6. Pharmacologic Management — What Is Indicated, What Is Contraindicated, and Why

7. Landmark Evidence — Key Trials and Guidelines in HFpEF

Clinical Reasoning Case — Acute Decompensated Heart Failure with Preserved EF

Stage 1 — Initial Differential Diagnosis + Anchor Trap Identification

Stage 2 — Precipitant Search + Evidence + HFpEF Pathophysiology

Stage 3 — Hemodynamic Profile + Urgent Actions + Must-Not-Miss

Stage 4A — Diagnostic and Management Orders (before results)

Stage 4B — Bayesian Update + Precipitant Inventory + Final Diagnosis + Treatment Plan

Stage 5 — Reasoning Chain + Cognitive Bias + Clinical Lesson

Scoring Rubric (Faculty Use) — 20 points total